In the recent years, several studies have shown the antifungal effect of "non-antifungal drugs" against true pathogenic species (Afeltra & Verweij 2003 , Chapman et al. 2008 , Cordeiro et al. 2009 ). The search for new antifungals is warranted because of the limited number of therapeutic drugs available for treating these infections. In addition, many researchers have been trying to improve the results obtained with antifungal monotherapy. Although data from controlled clinical trials are scarce, many recent reports have claimed beneficial effects of antifungal combinations for the treatment of severe fungal infections (Johnson & Perfect 2010 , Matsuda et al. 2010 .
Coccidioidomycosis is a deep fungal infection caused by the soil-dwelling ascomycetes Coccidioides spp. The disease has a broad clinical spectrum, ranging from a mild respiratory syndrome to progressive pneumonia and meningitis (Galgiani et al. 2005) . Although Coccidioides spp rarely display antifungal resistance in vitro (Kriesel et al. 2008) , specialists recognise that coccidioidomycosis is one of the most refractory fungal infections (Stevens et al. 2007 ). Therefore, several in vitro and in vivo studies have been performed in an attempt to identify new potential therapeutic drugs and antimicrobial combinations that can be used against Coccidioides spp (Shubitz et al. 2006 , González et al. 2007 , Cordeiro et al. 2009 .
In this study, we investigated the effect of cotrimoxazole -a wide-spectrum antimicrobial formed by sulfamethoxazole (SMX) plus trimethoprim (TMP) -on the in vitro susceptibility of Coccidioides posadasii to amphotericin B (AMB), currently the most important drug used to treat life-threatening forms of coccidioidomycosis.
A total of 18 strains of C. posadasii isolated in the state of Ceará (Northeast Brazil) from clinical (n = 15) and environmental (n = 3) sources were evaluated in this study. The strains of C. posadasii were obtained from storage in 0.9% saline at 4ºC, subcultured on Sabouraud glucose agar (Difco, Detroit, USA) and incubated at 25ºC for 10 days. Prior to antimicrobial testing, the viability and purity of each isolate were evaluated by microscopic examinations and polymerase chain reaction experiments described elsewhere (Cordeiro et al. 2010 ). All procedures were performed within a class II biological safety cabinet in a biosafety level 3 laboratory. Inoculum preparation was carried out as described by Cordeiro et al. (2009) . Sterile normal saline was added to each agar slant and the cultures were gently scraped with cotton swabs. The suspension was transferred to a sterile tube and allowed to settle for 5 min and then the transmittance of the upper homogeneous supernatant was read at 530 nm and adjusted to 95% transmittance. The suspension containing arthroconidia and hyphae was diluted 1:10 with RPMI 1640 medium containing Lglutamine and without sodium bicarbonate and buffered to pH 7.0 with 0.165 M MOPS to obtain an inoculum of approximately 1 x 10 3 -5 x 10 3 CFU/mL. Antifungal susceptibility assays were performed by the broth macrodilution method (M38-A2) according to CLSI (2008) standards guidelines. First, the strains were tested against each antimicrobial alone to determine the minimum inhibitory concentrations (MICs). The drug concentration ranges tested were as follows: AMB, 0.0625-1.0 μg/mL; ITR, 0.0625-1.0 μg/mL; VRZ, 0.031-0.5 μg/mL; FLC, 0.78-12.5 μg/mL; SMX-TMP, 250/50-4,000/800 μg/mL. The procedures were repeated at least twice and each fungal strain was tested in duplicate. MICs for AMB and azoles were defined as the lowest concentration of the drug at which there was no visible fungal growth (CLSI 2008) . We defined the MIC of SMX/TMP as the lowest drug concentration that caused 80% inhibition of visible fungal growth. After MIC definition for each drug, the strains were tested against the combination AMB/SMX/TMP. The following concentrations were tested: AMB, 0.007-0.116 µg/mL; SMX/ TMP, 125/25-2,000/400 µg/mL. The MIC of each drug in combination was defined as the lowest concentration that caused 80% inhibition of visible fungal growth.
The non-parametric Wilcoxon Signed Rank Test was used for analysis of the antimicrobial combinations. The results were expressed as the mean and a p value of < 0.05 was considered significant. The MIC (geometric means) was 0.111 µg/mL, 0.155 µg/mL, 4.819 µg/mL and 0.142 µg/mL for AMB, ITR, FLC and VRZ, respectively. The antimicrobial combination SMX/TMP was also able to inhibit the growth of all C. posadasii strains in vitro and the MIC values ranged from 1,000/200-2,000/400 μg/mL (Table I) . When used in combination with SMX/TMP, the MICs of the antifungals were reduced by 11, 2.4, 4.3 and 3.5 times for AMB, ITR, FLC and VRZ, respectively (p < 0.05) (Table II) . Sulpha derivatives are antimetabolic drugs that impair folic acid synthesis in microorganisms. These compounds have a broad antimicrobial spectrum and are active against several aerobic bacteria and some protozoan species and these compounds are frequently used successfully for the treatment and prevention of pneumonia caused by Pneumocystis jiroveci in acquired immune deficiency syndrome patients (Thomas et al. 2009 ). Although these compounds are not common first-line drugs in the management of fungal infections, the combination of SMX/ TMP has shown good results in treating paracoccidioidomycosis (Hahn et al. 2003 , Wanke & Aidê 2009 ). Our results show that SMX/TMP was able to enhance the susceptibility of C. posadasii to AMB by reducing the AMB MIC by approximately 5.85 times. Surprisingly, it was shown that the combination SMX/TMP alone was also able to impair C. posadasii growth in vitro.
In a previous work, Hanafy et al. (2007) found a great variability among SMX MICs against Cryptococcus sp. The authors reported that higher MIC values were attained when susceptibility tests were performed in organic-rich media because para-aminobenzoic acid (PABA) or PABA-related compounds may be present. In this study, we tried to perform the susceptibility tests with yeast nitrogen base, as suggested by Hanafy et al. (2007) , but unfortunately this medium did not support the growth of C. posadasii (data not shown). Because other studies have already been performed with RPMI (Yekutiel et al. 2004 , Navarro-Martinez et al. 2006 , we decided to evaluate this medium in our experiments. However, we assumed that in PABA-free medium, SMX/ TMP may cause a greater reduction in AMB MICs.
We hypothesise that low concentrations of AMB may have caused slight damage to the fungal plasmatic membrane, allowing moderate ion leakage. In addition, these channels across the membrane may have allowed SMX/TMP to enter the cell. Therefore, we believe that acid folic blockade may be a potential target for C. posadasii inhibition. The design of sulpha drugs with higher affinity for dihydrofolate reductase or other folic acid biosynthetic pathway enzymes could enhance fungal in-hibition. In fact, this pathway seems to be determinant of fungal viability, as Aspergillus fumigatus mutants defective in folate biosynthesis have been shown to be avirulent (Brown et al. 2000) .
According to Navarro-Martinez et al. (2006) , interruption of the folic acid biosynthetic pathway also impairs ergosterol production in Candida albicans, possibly by disturbing the metabolism of sterol C24 methyltransferase because the synthesis of its substrate is also blocked. It is well-known that ergosterol biosynthesis is also interrupted by azole antifungals agents that act on sterol 14 α-demethylase enzyme. The synergistic effect of these drugs was demonstrated in this study.
Although it is reasonable to suppose that the results of susceptibility tests against the parasitic form of C. posadasii are more reliable, very few studies have tested the susceptibility pattern of the yeast-like form of the fungus because the transition from mycelia to yeast it is not easily achieved (Hector et al. 1988) . In contrast, tests with cells in the saprophytic phase are easier to perform and, even though CLSI protocols are not intended for testing dimorphic fungi, these protocols can be applied, generating results that are easy to compare.
The results obtained in this study demonstrate the potential of the SMX/TMP/AMB combination, which has an inhibitory effect on C. posadasii strains, even at sub-MIC concentrations of AMB. In addition, the results showed that SMX/TMP also has an inhibitory effect on C. posadasii, suggesting that acid folic blockade may be a potential antifungal target for C. posadasii. As far as we know, this is the first report of the antifungal potential of sulpha drugs against this pathogen.
